Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for XENE

Stock Name	Xenon Pharmaceuticals Inc
Ticker	XENE(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	CA98420N1050

Show aggregate XENE holdings

News associated with XENE

Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE): Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock traders bought 4,063 put options on the stock. This represents an increase of approximately 2,362% compared to the average volume of 165 put options. Institutional Trading of Xenon Pharmaceuticals Institutional investors have recently modified their holdings […] - 2025-09-18 04:48:00
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE): Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the target of some unusual options trading activity on Wednesday. Stock investors purchased 4,063 put options on the company. Thisrepresentsanincreaseofapproximately2,362% compared to the typical volume of 165 put options. Analyst Ratings Changes A number of analysts have weighed in on the stock. Wall Street Zen downgraded […] - 2025-08-22 02:22:44
Royal Bank Of Canada Issues Pessimistic Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price: Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) had its price target decreased by analysts at Royal Bank Of Canada from $57.00 to $55.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target indicates a potential upside of 46.00% […] - 2025-08-14 02:13:05
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Expected to Rise, Wedbush Analyst Says: Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) had its price target upped by stock analysts at Wedbush from $42.00 to $43.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Wedbush’s target price indicates a potential upside of 14.15% from […] - 2025-08-14 02:13:01
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up on Analyst Upgrade: Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) shares gapped up before the market opened on Tuesday after Wedbush raised their price target on the stock from $42.00 to $43.00. The stock had previously closed at $34.11, but opened at $36.00. Wedbush currently has an outperform rating on the stock. Xenon Pharmaceuticals shares last traded […] - 2025-08-13 02:36:44
11,949 Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Acquired by Y Intercept Hong Kong Ltd: Y Intercept Hong Kong Ltd bought a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,949 shares of the biopharmaceutical company’s stock, valued at approximately $401,000. Other large investors […] - 2025-07-29 05:16:54
Investors Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE): Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) saw unusually large options trading on Wednesday. Traders acquired 4,063 put options on the company. This is an increase of 2,362% compared to the average daily volume of 165 put options. Institutional Inflows and Outflows Large investors have recently made changes to their positions in the stock. […] - 2025-07-24 04:56:56
New York State Common Retirement Fund Buys 9,851 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE): New York State Common Retirement Fund lifted its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 7.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 142,372 shares of the biopharmaceutical company’s stock after acquiring an additional 9,851 […] - 2025-07-22 07:10:51
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE): Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) saw unusually large options trading on Wednesday. Traders bought 4,063 put options on the company. This is an increase of 2,362% compared to the typical daily volume of 165 put options. Hedge Funds Weigh In On Xenon Pharmaceuticals Several large investors have recently modified their holdings of […] - 2025-06-26 03:00:54
Comparing Xenon Pharmaceuticals (NASDAQ:XENE) & Inhibitor Therapeutics (OTCMKTS:INTI): Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) and Inhibitor Therapeutics (OTCMKTS:INTI – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation. Insider & Institutional Ownership 95.4% of Xenon Pharmaceuticals […] - 2025-06-04 03:06:45
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of “Buy” from Brokerages: Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) have earned an average recommendation of “Buy” from the twelve ratings firms that are currently covering the stock, Marketbeat Ratings reports. Twelve equities research analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have updated their coverage […] - 2025-05-26 04:40:52
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Lowered by StockNews.com: Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday. Other equities research analysts have also issued reports about the stock. Evercore ISI assumed coverage on shares of Xenon Pharmaceuticals in a research note […] - 2025-05-21 05:12:51
D. E. Shaw & Co. Inc. Sells 117,919 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE): D. E. Shaw & Co. Inc. lowered its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 57.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 86,973 shares of the biopharmaceutical company’s stock after selling 117,919 shares during the quarter. D. […] - 2025-05-19 05:12:55
Xenon Pharmaceuticals (NASDAQ:XENE) Given New $47.00 Price Target at Wells Fargo & Company: Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) had its target price cut by Wells Fargo & Company from $50.00 to $47.00 in a research report report published on Tuesday, Marketbeat.com reports. They currently have an overweight rating on the biopharmaceutical company’s stock. Several other research analysts also recently issued reports on the company. William Blair reaffirmed […] - 2025-05-16 03:05:00
Needham & Company LLC Cuts Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $55.00: Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) had its price target trimmed by Needham & Company LLC from $60.00 to $55.00 in a research report report published on Tuesday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently issued reports on XENE. The Goldman Sachs […] - 2025-05-16 03:04:59
Chardan Capital Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE): Chardan Capital reaffirmed their buy rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a report issued on Tuesday,Benzinga reports. The firm currently has a $55.00 price objective on the biopharmaceutical company’s stock. Several other research firms also recently commented on XENE. Royal Bank of Canada reiterated an “outperform” rating on shares of […] - 2025-05-16 03:04:56
Traders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE): Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the target of unusually large options trading activity on Wednesday. Stock investors purchased 4,063 put options on the stock. This is an increase of 2,362% compared to the typical daily volume of 165 put options. Analysts Set New Price Targets Several research analysts recently issued reports […] - 2025-05-15 04:31:06
Royal Bank of Canada Issues Pessimistic Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price: Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) had its price target reduced by equities research analysts at Royal Bank of Canada from $58.00 to $55.00 in a research report issued to clients and investors on Tuesday, MarketBeat reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s target […] - 2025-05-15 02:48:49
HC Wainwright Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE): Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $53.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 78.21% from the stock’s previous close. Other research analysts […] - 2025-05-15 02:48:48
StockNews.com Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to “Hold”: Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Tuesday. A number of other equities research analysts have also recently commented on XENE. Royal Bank of Canada cut their target price on Xenon Pharmaceuticals from $58.00 to […] - 2025-05-15 02:16:49
Raymond James Financial Inc. Invests $797,000 in Xenon Pharmaceuticals Inc. (NASDAQ:XENE): Raymond James Financial Inc. purchased a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 20,331 shares of the biopharmaceutical company’s stock, valued at approximately $797,000. A number of […] - 2025-05-07 04:38:48
William Blair Reiterates Outperform Rating for Xenon Pharmaceuticals (NASDAQ:XENE): Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at William Blair in a note issued to investors on Monday,RTT News reports. XENE has been the topic of several other reports. The Goldman Sachs Group dropped their target price on Xenon Pharmaceuticals from $60.00 to $52.00 and set […] - 2025-05-07 02:22:49
Xenon Pharmaceuticals (NASDAQ:XENE) Cut to “Sell” at StockNews.com: StockNews.com downgraded shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) from a hold rating to a sell rating in a report released on Friday morning. XENE has been the topic of several other reports. Deutsche Bank Aktiengesellschaft started coverage on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a […] - 2025-05-05 02:28:52
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE): Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the target of unusually large options trading on Wednesday. Stock investors acquired 4,063 put options on the company. This is an increase of approximately 2,362% compared to the average daily volume of 165 put options. Xenon Pharmaceuticals Stock Performance XENE opened at $38.20 on Thursday. The […] - 2025-05-01 04:46:54
Guggenheim Capital LLC Decreases Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE): Guggenheim Capital LLC lowered its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 41.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,177 shares of the biopharmaceutical company’s stock after selling 4,452 shares during the quarter. Guggenheim Capital LLC’s holdings in […] - 2025-04-29 05:30:55
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $56.78 Consensus PT from Analysts: Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) has been given a consensus recommendation of “Buy” by the ten analysts that are presently covering the firm, MarketBeat reports. Ten investment analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have updated their coverage on the stock […] - 2025-04-29 03:10:55
Invesco Ltd. Cuts Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE): Invesco Ltd. cut its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 2.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 209,554 shares of the biopharmaceutical company’s stock after selling 6,268 shares during the quarter. […] - 2025-04-24 05:00:53
Traders Purchase Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE): Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the target of unusually large options trading on Wednesday. Traders acquired 4,063 put options on the company. This is an increase of 2,362% compared to the typical daily volume of 165 put options. Wall Street Analyst Weigh In A number of analysts have commented on the […] - 2025-04-17 04:41:09
Xenon Pharmaceuticals (NASDAQ:XENE) Rating Lowered to Sell at StockNews.com: Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Wednesday. Several other equities research analysts have also recently commented on XENE. William Blair reissued an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Friday, […] - 2025-04-16 03:10:56
Trexquant Investment LP Has $447,000 Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE): Trexquant Investment LP trimmed its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 32.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,397 shares of the biopharmaceutical company’s stock after selling 5,510 shares during the period. Trexquant […] - 2025-04-13 05:31:04

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) XENE holdings

Date	Number of XENE Shares Held	Base Market Value of XENE Shares	Local Market Value of XENE Shares	Change in XENE Shares Held	Change in XENE Base Value	Current Price per XENE Share Held	Previous Price per XENE Share Held
2025-11-11 (Tuesday)	50,341	USD 2,009,613	USD 2,009,613	0	USD 76,015	USD 39.92	USD 38.41
2025-11-10 (Monday)	50,341	USD 1,933,598	USD 1,933,598	129	USD 12,989	USD 38.41	USD 38.25
2025-11-07 (Friday)	50,212	USD 1,920,609	USD 1,920,609	0	USD -2,511	USD 38.25	USD 38.3
2025-11-06 (Thursday)	50,212	USD 1,923,120	USD 1,923,120	129	USD -13,089	USD 38.3	USD 38.66
2025-11-05 (Wednesday)	50,083	USD 1,936,209	USD 1,936,209	0	USD -21,535	USD 38.66	USD 39.09
2025-11-04 (Tuesday)	50,083	USD 1,957,744	USD 1,957,744	129	USD -96,364	USD 39.09	USD 41.12
2025-11-03 (Monday)	49,954	USD 2,054,108	USD 2,054,108	0	USD -39,964	USD 41.12	USD 41.92
2025-10-31 (Friday)	49,954	USD 2,094,072	USD 2,094,072	0	USD -37,465	USD 41.92	USD 42.67
2025-10-30 (Thursday)	49,954	USD 2,131,537	USD 2,131,537	645	USD 45,766	USD 42.67	USD 42.3
2025-10-29 (Wednesday)	49,309	USD 2,085,771	USD 2,085,771	258	USD -368	USD 42.3	USD 42.53
2025-10-28 (Tuesday)	49,051	USD 2,086,139	USD 2,086,139	0	USD 31,393	USD 42.53	USD 41.89
2025-10-27 (Monday)	49,051	USD 2,054,746	USD 2,054,746	0	USD 55,427	USD 41.89	USD 40.76

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of XENE by Blackrock for IE00BDZVHG35

Show aggregate share trades of XENE

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 BUY 129 38.410* 36.76
2025-11-06 BUY 129 38.300* 36.75
2025-11-04 BUY 129 39.090* 36.72
2025-10-30 BUY 645 42.955 41.850 41.960 USD 27,065 36.64
2025-10-29 BUY 258 42.300 42.765 42.718 USD 11,021 36.60
2025-10-22 SELL -516 42.180 43.280 43.170 USD -22,276 36.46 Loss of -3,464 on sale
2025-10-20 BUY 258 43.440 44.230 44.151 USD 11,391 36.38
2025-10-17 BUY 645 41.630 42.940 42.809 USD 27,612 36.35
2025-10-15 BUY 1,032 41.900 42.185 42.157 USD 43,506 36.31
2025-10-03 BUY 889 39.610 40.170 40.114 USD 35,661 36.27
2025-10-02 BUY 127 39.200 39.410 39.389 USD 5,002 36.25
2025-09-30 BUY 254 40.150 40.355 40.334 USD 10,245 36.21
2025-09-26 BUY 254 37.980 38.060 38.052 USD 9,665 36.18
2025-09-25 BUY 254 36.520 36.845 36.813 USD 9,350 36.18
2025-09-18 BUY 134 37.760 37.840 37.832 USD 5,069 36.17
2025-09-17 BUY 402 36.700 37.990 37.861 USD 15,220 36.17
2025-07-17 SELL -268 32.120 32.410 32.381 USD -8,678 36.26 Profit of 1,038 on sale
2025-07-16 BUY 850 31.620 32.100 32.052 USD 27,244 36.29
2025-07-11 SELL -1,048 32.210 33.150 33.056 USD -34,643 36.37 Profit of 3,471 on sale
2025-07-02 BUY 7,205 33.370 33.440 33.433 USD 240,885 36.46
2025-06-25 BUY 262 31.760 32.370 32.309 USD 8,465 36.59
2025-06-20 BUY 939 32.050 32.720 32.653 USD 30,661 36.69
2025-06-13 BUY 831 32.760 33.460 33.390 USD 27,747 36.86
2025-06-11 BUY 252 32.260 33.120 33.034 USD 8,325 36.92
2025-06-10 BUY 252 32.160 32.590 32.547 USD 8,202 36.96
2025-06-04 SELL -126 30.460 31.245 31.167 USD -3,927 37.14 Profit of 753 on sale
2025-04-23 BUY 125 37.590 38.550 38.454 USD 4,807 38.34
2025-04-10 SELL -1,000 30.730 31.800 31.693 USD -31,693 38.80 Profit of 7,103 on sale
2025-04-08 SELL -125 28.230 31.430 31.110 USD -3,889 39.00 Profit of 986 on sale
2025-04-07 SELL -125 30.630 31.520 31.431 USD -3,929 39.10 Profit of 958 on sale
2025-04-04 SELL -630 29.400 30.760 30.624 USD -19,293 39.21 Profit of 5,410 on sale
2025-04-01 BUY 524 30.640 33.640 33.340 USD 17,470 39.41
2025-03-31 SELL -378 33.550 33.795 33.770 USD -12,765 39.48 Profit of 2,158 on sale
2025-03-21 BUY 1,792 35.340 35.630 35.601 USD 63,797 39.83
2025-03-14 SELL -1,920 35.320 36.245 36.152 USD -69,413 40.16 Profit of 7,692 on sale
2025-03-07 SELL -240 36.500 38.080 37.922 USD -9,101 40.53 Profit of 626 on sale
2025-03-04 SELL -120 36.020 37.270 37.145 USD -4,457 40.71 Profit of 428 on sale
2025-02-25 BUY 240 37.650 38.520 38.433 USD 9,224 40.98
2025-02-19 SELL -119 38.500 39.730 39.607 USD -4,713 41.13 Profit of 181 on sale
2025-02-13 BUY 357 39.260 39.840 39.782 USD 14,202 41.29
2025-02-12 BUY 119 39.500 39.520 39.518 USD 4,703 41.33
2025-02-11 BUY 476 38.390 39.594 39.474 USD 18,789 41.39
2024-12-30 SELL -3,816 38.530 39.000 38.953 USD -148,645 42.11 Profit of 12,037 on sale
2024-11-18 SELL -1,938 38.310 40.040 39.867 USD -77,262 42.78 Profit of 5,649 on sale
2024-11-08 SELL -129 45.000 46.000 45.900 USD -5,921 42.58 Loss of -428 on sale
2024-10-21 SELL -130 44.210 44.840 44.777 USD -5,821 0.00 Loss of -5,821 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	BUY	129			38.410*		36.76
2025-11-06	BUY	129			38.300*		36.75
2025-11-04	BUY	129			39.090*		36.72
2025-10-30	BUY	645	42.955	41.850	41.960	USD 27,065	36.64
2025-10-29	BUY	258	42.300	42.765	42.718	USD 11,021	36.60
2025-10-22	SELL	-516	42.180	43.280	43.170	USD -22,276	36.46 Loss of -3,464 on sale
2025-10-20	BUY	258	43.440	44.230	44.151	USD 11,391	36.38
2025-10-17	BUY	645	41.630	42.940	42.809	USD 27,612	36.35
2025-10-15	BUY	1,032	41.900	42.185	42.157	USD 43,506	36.31
2025-10-03	BUY	889	39.610	40.170	40.114	USD 35,661	36.27
2025-10-02	BUY	127	39.200	39.410	39.389	USD 5,002	36.25
2025-09-30	BUY	254	40.150	40.355	40.334	USD 10,245	36.21
2025-09-26	BUY	254	37.980	38.060	38.052	USD 9,665	36.18
2025-09-25	BUY	254	36.520	36.845	36.813	USD 9,350	36.18
2025-09-18	BUY	134	37.760	37.840	37.832	USD 5,069	36.17
2025-09-17	BUY	402	36.700	37.990	37.861	USD 15,220	36.17
2025-07-17	SELL	-268	32.120	32.410	32.381	USD -8,678	36.26 Profit of 1,038 on sale
2025-07-16	BUY	850	31.620	32.100	32.052	USD 27,244	36.29
2025-07-11	SELL	-1,048	32.210	33.150	33.056	USD -34,643	36.37 Profit of 3,471 on sale
2025-07-02	BUY	7,205	33.370	33.440	33.433	USD 240,885	36.46
2025-06-25	BUY	262	31.760	32.370	32.309	USD 8,465	36.59
2025-06-20	BUY	939	32.050	32.720	32.653	USD 30,661	36.69
2025-06-13	BUY	831	32.760	33.460	33.390	USD 27,747	36.86
2025-06-11	BUY	252	32.260	33.120	33.034	USD 8,325	36.92
2025-06-10	BUY	252	32.160	32.590	32.547	USD 8,202	36.96
2025-06-04	SELL	-126	30.460	31.245	31.167	USD -3,927	37.14 Profit of 753 on sale
2025-04-23	BUY	125	37.590	38.550	38.454	USD 4,807	38.34
2025-04-10	SELL	-1,000	30.730	31.800	31.693	USD -31,693	38.80 Profit of 7,103 on sale
2025-04-08	SELL	-125	28.230	31.430	31.110	USD -3,889	39.00 Profit of 986 on sale
2025-04-07	SELL	-125	30.630	31.520	31.431	USD -3,929	39.10 Profit of 958 on sale
2025-04-04	SELL	-630	29.400	30.760	30.624	USD -19,293	39.21 Profit of 5,410 on sale
2025-04-01	BUY	524	30.640	33.640	33.340	USD 17,470	39.41
2025-03-31	SELL	-378	33.550	33.795	33.770	USD -12,765	39.48 Profit of 2,158 on sale
2025-03-21	BUY	1,792	35.340	35.630	35.601	USD 63,797	39.83
2025-03-14	SELL	-1,920	35.320	36.245	36.152	USD -69,413	40.16 Profit of 7,692 on sale
2025-03-07	SELL	-240	36.500	38.080	37.922	USD -9,101	40.53 Profit of 626 on sale
2025-03-04	SELL	-120	36.020	37.270	37.145	USD -4,457	40.71 Profit of 428 on sale
2025-02-25	BUY	240	37.650	38.520	38.433	USD 9,224	40.98
2025-02-19	SELL	-119	38.500	39.730	39.607	USD -4,713	41.13 Profit of 181 on sale
2025-02-13	BUY	357	39.260	39.840	39.782	USD 14,202	41.29
2025-02-12	BUY	119	39.500	39.520	39.518	USD 4,703	41.33
2025-02-11	BUY	476	38.390	39.594	39.474	USD 18,789	41.39
2024-12-30	SELL	-3,816	38.530	39.000	38.953	USD -148,645	42.11 Profit of 12,037 on sale
2024-11-18	SELL	-1,938	38.310	40.040	39.867	USD -77,262	42.78 Profit of 5,649 on sale
2024-11-08	SELL	-129	45.000	46.000	45.900	USD -5,921	42.58 Loss of -428 on sale
2024-10-21	SELL	-130	44.210	44.840	44.777	USD -5,821	0.00 Loss of -5,821 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of XENE

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	94,121	0	116,537	80.8%
2025-09-18	166,160	0	196,562	84.5%
2025-09-17	153,610	0	353,729	43.4%
2025-09-16	127,586	0	236,754	53.9%
2025-09-15	95,792	14	178,183	53.8%
2025-09-12	70,043	0	198,178	35.3%
2025-09-11	96,068	0	181,331	53.0%
2025-09-10	122,078	0	189,803	64.3%
2025-09-09	90,865	0	283,996	32.0%
2025-09-08	232,027	100	301,530	76.9%
2025-09-05	156,900	0	238,492	65.8%
2025-09-04	166,307	0	271,514	61.3%
2025-09-03	157,066	0	271,074	57.9%
2025-09-02	81,739	0	248,041	33.0%
2025-08-29	152,207	0	232,164	65.6%
2025-08-28	61,706	0	157,013	39.3%
2025-08-27	83,791	0	140,984	59.4%
2025-08-26	138,841	12	233,008	59.6%
2025-08-25	90,644	0	153,535	59.0%
2025-08-22	241,402	0	680,379	35.5%
2025-08-21	240,881	0	412,449	58.4%
2025-08-20	121,216	0	174,820	69.3%
2025-08-19	140,464	0	214,610	65.5%
2025-08-18	180,294	0	305,703	59.0%
2025-08-15	160,339	2,610	215,321	74.5%
2025-08-14	238,992	0	350,208	68.2%
2025-08-13	372,443	0	746,027	49.9%
2025-08-12	467,887	0	696,577	67.2%
2025-08-11	270,332	55	374,372	72.2%
2025-08-08	242,928	90	362,883	66.9%
2025-08-07	167,847	368	222,326	75.5%
2025-08-06	192,634	0	261,533	73.7%
2025-08-05	641,973	50	1,267,219	50.7%
2025-08-04	456,814	0	843,073	54.2%
2025-08-01	190,981	5,139	229,705	83.1%
2025-07-31	195,002	781	223,443	87.3%
2025-07-30	154,824	900	252,506	61.3%
2025-07-29	243,814	1,587	303,064	80.4%
2025-07-28	320,579	0	650,128	49.3%
2025-07-25	214,658	100	341,862	62.8%
2025-07-24	138,436	0	204,720	67.6%
2025-07-23	119,232	0	205,068	58.1%
2025-07-22	103,454	0	214,734	48.2%
2025-07-21	212,989	0	246,308	86.5%
2025-07-18	176,030	0	205,045	85.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE